Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Public Citizen Urges “Black Box” On Vision Loss For Erectile Dysfunction Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

The advocacy group’s petition also asks FDA to require that manufacturers establish a patient registry to track cases of non-arteritic ischemic optic neuropathy.

You may also be interested in...

Pfizer Turns To Lipitor DTC To Pump Up Lipid-Lowering Market

Pfizer hopes new branded and unbranded ads will reinvigorate the cholesterol-lowering category following flat third-quarter sales for the statin in the U.S.

FDA Public Education On ED Drug Vision Risk Is Lacking, Sen. Grassley Says

Senate Finance Committee chair seeks FDA strategy for disseminating drug safety information to patients not requiring physician follow-up.

Erectile Dysfunction Class Labeling Does Not Assert Causal Link To Vision Loss

Labeling revisions for Viagra, Levitra and Cialis will add information about NAION adverse events, but states that “it is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.”

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts